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Abstract: The new-generation hormonal agent enzalutamide has been approved for the 
treatment of metastatic castration-resistant prostate cancer (CRPC), in both post- and predocetaxel 
setting, due to the significant improvement in overall survival. More recently, enzalutamide also 
showed impressive results in the treatment of men with nonmetastatic CRPC. Unfortunately, 
not all patients with CRPC are responsive to enzalutamide, and even in responders, benefits 
are limited by the development of drug resistance. Adaptive resistance of metastatic prostate 
cancer to enzalutamide treatment can be due to the activation of both androgen receptor (AR)-
dependent pathways (expression of constitutively active AR splice variants, AR point mutations, 
gene amplification and overexpression) and mechanisms independent of AR signaling pathway 
(altered steroidogenesis, upregulation of the glucocorticoid receptor, epithelial–mesenchymal 
transition, neuroendocrine transformation, autophagy and activation of the immune system). 
In this review, we focus on resistance mechanisms to enzalutamide, exploring how we could 
overcome them through novel therapeutic options.
Keywords: prostate cancer, enzalutamide, hormonal treatment, mechanisms of resistance, 
castration-resistant prostate cancer, androgen receptor
Introduction
Prostate cancer (PC) is the most common nonskin cancer, accounting for almost one 
in every five new cancer diagnoses, and the second leading cause of cancer-related 
death among men in the USA.1
At the time of diagnosis, most men have localized disease amenable to curative 
surgery or radiotherapy (RT). However, ~5%–10% of PC presents with de novo meta-
static disease, and in addition, some patients will recur after local treatment. Five-year 
survival is almost 100% for localized and locally advanced disease, but it is ,30% in 
patients with metastatic disease.2
Because of the crucial role of androgen receptor (AR) in the development and 
progression of PC, the mainstay of therapy for relapsed or metastatic patients is rep-
resented by androgen deprivation therapy (ADT), achieved by either orchiectomy or 
medical castration with luteinizing hormone-releasing hormone (LHRH) agonists or 
antagonists. Despite initial high response rates (in the range of 80%–90%), nearly all 
men eventually develop progressive disease within some years (median 2–3 years) from 
the start of ADT, entering the so-called castration-resistant phase of the disease.
In the past years, many therapeutic advances have been achieved in metastatic 
castration-resistant PC (mCRPC), with the approval of several new drugs.3 Two new 
generation hormonal agents, abiraterone and enzalutamide, have shown an improve-
ment in overall survival (OS) in both post-4,5 and predocetaxel setting.6,7
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Cabazitaxel, an innovative taxane, is currently used in 
patients who have failed docetaxel-based chemotherapy.8,9
Radium-223, an alpha-emitting bone target agent, demon-
strated a prolongation of OS compared to placebo, regardless 
of previous treatment with docetaxel, and it was approved 
for symptomatic bone mCRPC patients.10
The Food and Drug Administration (FDA) also approved 
sipuleucel-T, an autologous cellular immunotherapy, for the 
treatment of asymptomatic or mild symptomatic castration-
resistant prostate cancer (CRPC) patients.11
In addition, to delay the establishment of a castration-
resistant condition, consequently improving patients’ quality 
of life and OS, the treatment paradigm of hormone-sensitive 
PC (HSPC) is changing too. At first, two randomized trials 
demonstrated a clinically relevant OS benefit, with the addi-
tion of six cycles of chemotherapy with docetaxel to standard 
ADT in metastatic HSPC patients.12–14
In the same setting, two trials have recently shown that 
adding abiraterone to ADT is associated with a significant 
OS prolongation in men with metastatic HSPC.15,16
Finally, one of the current therapeutic end points is to 
anticipate treatment to delay the appearance of metastasis in 
high-risk nonmetastatic CRPC patients. Based on the results 
of SPARTAN trial, in which apalutamide reduced the RR 
of metastasis or death by more than 70% compared to pla-
cebo, the FDA has recently approved this drug for patients 
with nonmetastatic CRPC.17 Overlapping results have been 
observed with enzalutamide in the PROSPER trial.18
Despite the large list of recent positive studies and 
therapeutic improvements, all these treatments have limited 
benefits, and sooner or later acquired drug resistance appears. 
In this review, we focus on the mechanisms of resistance to 
enzalutamide.
Enzalutamide
Enzalutamide is an oral AR inhibitor, with affinity for its 
target eightfold higher than bicalutamide. Unlike bicalut-
amide, which acts only at the receptor level, enzalutamide 
also prevents AR nuclear translocation, DNA binding and 
coactivator recruitment.19
Initially, enzalutamide was evaluated in the postdocetaxel 
setting, in the context of AFFIRM, a Phase III randomized, 
double-blind, placebo-controlled study, which enrolled 
1,199 CRPC patients. Enzalutamide showed a significant 
improvement in OS compared to placebo: median OS was 
18.4 vs 13.6 months, HR 0.63, 95% CI 0.53–0.75, P,0.0001. 
Enzalutamide maintained its superiority over placebo in all 
secondary end points, including time to prostate-specific 
antigen (PSA) progression (median 8.3 vs 3.0 months, 
HR 0.25, P,0.001), soft tissue response rate (29% vs 4%, 
P,0.001) and improvement in the quality of life (43% vs 
18%, P,0.001).5
Subsequently, enzalutamide was evaluated in chemother-
apy-naïve patients with progressive mCRPC. In the Phase III 
PREVAIL study, 1,717 men were randomized to receive 
enzalutamide or placebo. Treatment with enzalutamide, 
compared to placebo, showed a statistically significant 29% 
reduction in the risk of death (HR 0.71, 95% CI 0.60–0.84, 
P,0.001) and an 81% reduction in the risk of radiological 
progression (HR 0.19, 95% CI 0.15–0.29, P,0.0001).7
Enzalutamide is usually well tolerated, and the most 
common adverse events (AEs; occurring in $5% of patients) 
are fatigue, hot flashes, diarrhea, hypertension and muscu-
loskeletal pain.5,7
Based on these data, the FDA and the European Medi-
cines Agency (EMA) granted approval for enzalutamide 
for the treatment of both docetaxel-naïve and docetaxel-
pretreated CRPC patients.
More recently, enzalutamide showed impressive results 
in the treatment of men with nonmetastatic CRPC, namely 
enzalutamide decreased the risk of distant metastasis or death 
by 71% (HR 0.29, 95% CI 0.24–0.35, P,0.0001) with an 
improvement of 21.9 months (36.6 months vs 14.7 months) 
in median metastasis-free survival.18
AR: structure and mechanism 
of action
AR is a nuclear ligand-activated transcriptional factor, a 
member of the steroid hormone nuclear receptor family, 
whose coding gene is located on chromosome 10. The AR 
consists of four functional domains: the N-terminal transac-
tivation domain (NTTD), the DNA-binding domain (DBD), 
the hinge region and the ligand-binding domain (LBD). Main 
ligands are the male sexual hormones such as testosterone 
and dihydrotestosterone; adrenal androgens bind the AR 
to lower affinity. AR binding to androgens induces a con-
formational change of the AR. The androgen–AR complex 
may translocate to the nucleus, dimerize and bind to specific 
androgen response elements (AREs), regulating target gene 
transcription. This process and the cross talk with other 
pathways are modulated by many coactivator and suppressor 
proteins. Regardless of the DNA binding, the androgen–AR 
complex may lead to a rapid phosphorylation of the second 
messenger pathways, such as ERK, AKT and MAPK.20 
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The AR normally promotes epithelial differentiation, but in 
PC, this pathway can modulate the expression of genes that 
regulate proliferation and survival of tumor cells.21
The adaptive response to androgen 
deprivation pressure
In recent years, scientific knowledge about PC biology and 
growth has substantially improved. Nowadays, it is well 
established that the progression from HSPC to CRPC is not 
determined by a true ADT resistance, but by an adaptation 
of PC cells to a microenvironment with reduced testosterone 
levels. In fact, notwithstanding the deep decrease in serum 
androgen levels caused by ADT, PC cells could synthe-
size androgens and could modify AR in a way that even 
low androgen levels could activate it.
The mechanisms responsible for this phenomenon are 
related to the selective pressure of ADT and include AR 
gene overexpression, AR gene mutation, AR variant of 
splicing (ARsv) expression, upregulation of transcriptional 
coactivators and overexpression of enzymes able to induce 
the production of androgens.19,21
Mechanisms of resistance to 
enzalutamide
Despite the therapeutic effect of enzalutamide in CRPC 
patients, a significant percentage of patients are primarily 
resistant or acquire resistance within a variable period of time 
following the start of enzalutamide treatment.19
Primary resistance is defined as the treatment failure within 
the first 3 months after the start of therapy, because of the deteri-
oration of clinical conditions, with or without radiological imag-
ing progression.22 On the other hand, acquired resistance consists 
in the treatment failure that arises later during treatment.
A comprehensive knowledge of the pathways associated 
with the development of both primary and acquired resistance 
remains a key factor to identify predictive factors of treatment 
efficacy and to investigate new therapeutic options.
Adaptive resistance of PC to enzalutamide treatment can 
be due to the activation of both AR-dependent pathways and 
mechanisms not dependent on AR signaling pathways.
Mechanisms of resistance dependent 
on AR signaling pathway
AR amplification and overexpression
Up to 80% of CRPC patients show AR protein overexpres-
sion, and in 20%–30% of patients, this is related to AR 
gene amplification.23 In vitro studies demonstrate that this 
alteration is more frequent in patients progressing on enzalu-
tamide than in treatment-naïve patients,24 and consequently, 
it is considered as a potential mechanism of resistance. In a 
cohort of patients previously treated with either enzalutamide 
or orteronel, a CYP17A inhibitor, 50% showed the evidence 
of AR amplification and only 13% had a clinically significant 
response when treated with abiraterone.24,25 These observa-
tions have been confirmed in a correlative biomarker study, 
in a cohort of 94 patients treated with enzalutamide in the 
context of the PREMIERE trial; AR-amplified tumors had 
a poor response to treatment and a largely shorter OS (HR 
11.08, 95% CI 2.16–56.95, P,0.004).26
A promising strategy to block AR overexpression consists 
in the administration of supraphysiologic doses of testosterone, 
that in the preclinical models prevented PC cell growth.27,28 
Unfortunately, this effect vanishes away in a short time, and 
PC cells progressively downregulate the AR, restoring cell 
growth in the presence of testosterone. A potential viable ther-
apeutic approach consists in the so-called “bipolar androgen 
therapy”, namely the swinging from supraphysiologic levels 
of androgens to near-castrate levels. The results of a Phase II 
trial testing this strategy in mCRPC patients after progression 
on enzalutamide have been recently published.29 Nine of the 
30 enrolled patients (30%; 95% CI 15%–49%) achieved a 
.50% PSA reduction, and 21 proceeded to enzalutamide 
rechallenge, with 15 patients (52%; 95% CI 33%–71%) 
experiencing .50% PSA reduction.29 Two Phase II trials are 
currently recruiting patients: the first (NCT02286921) aims 
to confirm the therapeutic benefits of the bipolar androgen 
therapy, while the second (NCT02090114) is designed to 
test the activity and efficacy of sustained supraphysiologic 
testosterone concentration (Table 1).
AR mutations
AR mutations, that are quite rare in untreated PC, can be 
detected in 5%–30% of CRPC patients treated with ADT, 
and their incidence may become relevantly higher during 
treatment with abiraterone and enzalutamide.
Most of the clinically relevant AR somatic point muta-
tions are located in the LBD, thus altering the steroid-binding 
pocket. This biochemical change leads to AR activation by 
alternative ligands, such as progesterone, hydrocortisone, 
oestradiol and some AR antagonists.24,30 One of the most 
frequently reported somatic mutations is F877L (previously 
reported in the literature as F876L), which has been identified 
in patients treated with enzalutamide and apalutamide (a new 
AR inhibitor). Both these drugs, binding to the mutated AR, 
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
19
2.
22
2.
29
 o
n 
29
-D
ec
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7356
Tucci et al
T
ab
le
 1
 P
ro
po
se
d 
st
ra
te
gi
es
 t
o 
ov
er
co
m
e 
en
za
lu
ta
m
id
e 
m
ec
ha
ni
sm
 o
f r
es
is
ta
nc
e,
 a
pp
ro
ve
d 
dr
ug
s 
an
d 
on
go
in
g 
cl
in
ic
al
 t
ri
al
M
ec
ha
ni
sm
 o
f 
re
si
st
an
ce
H
ow
 t
o 
ov
er
co
m
e 
it
O
ng
oi
ng
 c
lin
ic
al
 t
ri
al
s
St
at
us
 (
up
da
te
d 
to
 
M
ar
ch
 2
01
8)
A
pp
ro
ve
d 
dr
ug
 a
nd
 r
el
at
iv
e 
cl
in
ic
al
 
tr
ia
l
A
R
 o
ve
re
xp
re
ss
io
n
en
za
lu
ta
m
id
e+
te
st
os
te
ro
ne
N
C
T
02
28
69
21
: P
ha
se
 ii
R
ec
ru
iti
ng
N
C
T
02
09
01
14
: P
ha
se
 ii
R
ec
ru
iti
ng
A
R
 m
ut
at
io
ns
D
ar
ol
ut
am
id
e
N
C
T
02
20
06
14
 –
 A
R
A
M
iS
 t
ri
al
: P
ha
se
 ii
i
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
N
C
T
03
31
43
24
 –
 O
D
eN
Z
A
 t
ri
al
: P
ha
se
 ii
R
ec
ru
iti
ng
D
ar
ol
ut
am
id
e+
do
ce
ta
xe
l
N
C
T
02
79
96
02
 –
 A
R
A
Se
N
S 
tr
ia
l: 
Ph
as
e 
iii
R
ec
ru
iti
ng
A
pa
lu
ta
m
id
e
SP
A
R
T
A
N
 t
ri
al
: P
ha
se
 ii
i →
 F
D
A
 a
pp
ro
va
l 
in
 n
on
m
et
as
ta
tic
 h
ig
h-
ri
sk
 C
R
PC
A
pa
lu
ta
m
id
e+
ab
ir
at
er
on
e
N
C
T
02
25
77
36
: P
ha
se
 ii
i
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
N
C
T
03
36
07
21
: P
ha
se
 ii
R
ec
ru
iti
ng
N
C
T
03
09
88
36
: P
ha
se
 ii
R
ec
ru
iti
ng
N
C
T
03
17
38
59
: P
ha
se
 ii
N
ot
 y
et
 r
ec
ru
iti
ng
A
pa
lu
ta
m
id
e+
do
ce
ta
xe
l
N
C
T
03
09
32
72
: P
ha
se
 ii
R
ec
ru
iti
ng
A
pa
lu
ta
m
id
e+
do
ce
ta
xe
l+
ab
ir
at
er
on
e
N
C
T
02
91
31
96
: P
ha
se
 i
R
ec
ru
iti
ng
A
pa
lu
ta
m
id
e+
ev
er
ol
im
us
N
C
T
02
10
65
07
: P
ha
se
 i
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
A
R
vs
eP
i-5
06
 (
N
T
T
D
-b
in
di
ng
 A
R
 a
nt
ag
on
is
t)
N
C
T
02
60
61
23
: P
ha
se
 i/
ii
A
cc
ru
al
 t
er
m
in
at
ed
en
za
lu
ta
m
id
e+
ni
cl
os
am
id
e 
(A
R
v
7 
pr
ot
ea
so
m
ic
 d
eg
ra
da
tio
n)
N
C
T
03
12
39
78
: P
ha
se
 i
R
ec
ru
iti
ng
N
C
T
02
53
21
14
: P
ha
se
 i
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
Z
eN
00
36
94
 (
Be
T
 in
hi
bi
to
r)
N
C
T
02
71
19
56
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
G
S-
58
29
 (
Be
T
 in
hi
bi
to
r)
N
C
T
02
60
72
28
: P
ha
se
 i/
ii
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
G
SK
52
57
62
 (
Be
T
 in
hi
bi
to
r)
N
C
T
03
15
00
56
: P
ha
se
 i
R
ec
ru
iti
ng
A
lte
re
d 
st
er
oi
do
ge
ne
si
s
en
za
lu
ta
m
id
e+
in
do
m
et
ha
ci
n 
(A
K
R
1c
 in
hi
bi
to
r)
N
C
T
02
93
52
05
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
G
lu
co
co
rt
ic
oi
ds
 
re
ce
pt
or
D
ex
am
et
ha
so
ne
N
C
T
02
49
14
11
: p
ilo
t 
st
ud
y
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
C
O
R
T
12
52
81
N
C
T
03
43
79
41
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
m
ife
pr
is
to
ne
 (
G
R
 a
nd
 P
gR
 a
nt
ag
on
is
t)
N
C
T
02
01
22
96
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
eM
T
en
za
lu
ta
m
id
e+
m
et
fo
rm
in
 (
T
G
F-
β1
/S
T
A
T
3 
in
hi
bi
to
r)
N
C
T
02
33
91
68
: P
ha
se
 i
R
ec
ru
iti
ng
N
C
T
02
64
05
34
: P
ha
se
 ii
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
LY
21
57
29
9 
(T
G
F-
β 
in
hi
bi
to
r)
N
C
T
02
45
20
08
: P
ha
se
 ii
R
ec
ru
iti
ng
N
eu
ro
en
do
cr
in
e 
tr
an
sf
or
m
at
io
n
A
lis
er
tib
 (
A
U
R
-K
A
 in
hi
bi
to
r)
N
C
T
01
79
92
78
: P
ha
se
 ii
C
om
pl
et
ed
A
ct
iv
at
io
n 
of
 o
th
er
 
pa
th
w
ay
s
en
za
lu
ta
m
id
e+
A
Z
D
53
63
 (
A
K
T
 in
hi
bi
to
r)
N
C
T
03
31
05
41
: P
ha
se
 i
R
ec
ru
iti
ng
N
C
T
02
52
50
68
: P
ha
se
 ii
R
ec
ru
iti
ng
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
19
2.
22
2.
29
 o
n 
29
-D
ec
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2018:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7357
enzalutamide-resistant castration-resistant prostate cancer
en
za
lu
ta
m
id
e+
G
SK
26
36
77
1 
(P
i3
K
-β
 in
hi
bi
to
r)
N
C
T
02
21
50
96
: P
ha
se
 i
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
Bi
83
68
45
 (
iG
F1
/2
 in
hi
bi
to
r)
N
C
T
02
20
40
72
: P
ha
se
 ib
/ii
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
ev
er
ol
im
us
 (
m
T
O
R
 in
hi
bi
to
r)
N
C
T
02
12
50
84
: P
ha
se
 i
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
C
C
-1
15
 (
m
T
O
R
 in
hi
bi
to
r)
N
C
T
02
83
38
83
: P
ha
se
 i
R
ec
ru
iti
ng
M
LN
01
28
 (
m
T
O
R
 in
hi
bi
to
r)
N
C
T
02
09
15
31
: P
ha
se
 ii
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
LY
30
23
41
4 
(P
i3
K
/m
T
O
R
 d
ua
l i
nh
ib
ito
r)
N
C
T
02
40
70
54
: P
ha
se
 ii
R
ec
ru
iti
ng
im
m
un
e 
sy
st
em
 
ac
tiv
at
io
n
en
za
lu
ta
m
id
e+
pe
m
br
ol
iz
um
ab
 (
an
ti-
PD
-1
 c
he
ck
po
in
t 
in
hi
bi
to
r)
N
C
T
02
86
15
73
 –
 K
eY
N
O
T
e 
36
5:
 P
ha
se
 i
R
ec
ru
iti
ng
N
C
T
02
78
70
05
 –
 K
eY
N
O
T
e 
19
9:
 P
ha
se
 ii
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
ni
vo
lu
m
ab
 (
an
ti-
PD
-1
 c
he
ck
po
in
t 
in
hi
bi
to
r)
N
C
T
03
33
87
90
 –
 C
he
ck
m
at
e 
9K
D
: P
ha
se
 ii
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
at
ez
ol
iz
um
ab
 (
an
ti-
PD
-L
1 
ch
ec
kp
oi
nt
 in
hi
bi
to
r)
N
C
T
03
01
63
12
 –
 iM
ba
ss
ad
or
25
0:
 P
ha
se
 ii
i
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
A
Z
D
50
69
 (
C
X
C
R
2 
in
hi
bi
to
r)
N
C
T
03
17
71
87
: P
ha
se
 i/
ii
N
ot
 y
et
 r
ec
ru
iti
ng
Si
pu
le
uc
el
-T
 (
au
to
lo
go
us
 c
el
lu
la
r 
im
m
un
ot
he
ra
py
)
iM
PA
C
T
 s
tu
dy
 –
 F
D
A
 a
pp
ro
va
l i
n 
m
C
R
PC
A
ss
oc
ia
tio
n 
w
ith
 
ch
em
ot
he
ra
py
en
za
lu
ta
m
id
e+
do
ce
ta
xe
l
N
C
T
03
24
63
47
: P
ha
se
 ii
R
ec
ru
iti
ng
N
C
T
02
28
82
47
: P
ha
se
 ii
i
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
ca
ba
zi
ta
xe
l
N
C
T
02
52
27
15
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
en
za
lu
ta
m
id
e+
pr
ed
ni
so
ne
+c
ab
az
ita
xe
l+
ab
ir
at
er
on
e
N
C
T
03
11
05
88
N
ot
 y
et
 r
ec
ru
iti
ng
PA
R
P 
in
hi
bi
to
rs
R
uc
ap
ar
ib
N
C
T
02
97
59
34
: P
ha
se
 ii
i
R
ec
ru
iti
ng
N
C
T
02
95
25
34
 –
 T
R
iT
O
N
2:
 P
ha
se
 ii
R
ec
ru
iti
ng
N
C
T
02
97
59
34
 –
 T
R
iT
O
N
3:
 P
ha
se
 ii
i
R
ec
ru
iti
ng
R
uc
ap
ar
ib
+c
ar
bo
pl
at
in
+d
oc
et
ax
el
N
C
T
03
44
25
56
: P
ha
se
 ii
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
O
la
pa
ri
b
N
C
T
03
04
71
35
: P
ha
se
 ii
R
ec
ru
iti
ng
N
C
T
01
07
86
62
: P
ha
se
 ii
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
O
la
pa
ri
b+
ab
ir
at
er
on
e
N
C
T
01
97
22
17
: P
ha
se
 ii
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
N
C
T
03
01
23
21
: P
ha
se
 ii
R
ec
ru
iti
ng
O
la
pa
ri
b+
R
ad
iu
m
-2
23
N
C
T
03
31
73
92
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
O
la
pa
ri
b±
ce
di
ra
ni
b
N
C
T
02
89
39
17
: P
ha
se
 ii
R
ec
ru
iti
ng
O
la
pa
ri
b+
M
eD
i4
73
6 
± 
ce
di
ra
ni
b
N
C
T
02
48
44
04
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
T
al
az
op
ar
ib
+a
ve
lu
m
ab
N
C
T
03
33
04
05
: P
ha
se
 i/
ii
R
ec
ru
iti
ng
v
el
ip
ar
ib
N
C
T
00
89
27
36
: P
ha
se
 i
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
v
el
ip
ar
ib
+a
bi
ra
te
ro
ne
N
C
T
01
57
61
72
: P
ha
se
 ii
A
ct
iv
e,
 n
ot
 r
ec
ru
iti
ng
N
ir
ap
ar
ib
N
C
T
02
85
44
36
: P
ha
se
 ii
R
ec
ru
iti
ng
A
bb
re
vi
at
io
ns
: A
R
, a
nd
ro
ge
n 
re
ce
pt
or
; A
R
vs
, A
R
 s
pl
ic
e 
va
ri
an
ts
; C
R
PC
, c
as
tr
at
io
n-
re
si
st
an
t 
pr
os
ta
te
 c
an
ce
r;
 e
M
T
, e
pi
th
el
ia
l–
m
es
en
ch
ym
al
 t
ra
ns
iti
on
; F
D
A
, F
oo
d 
an
d 
D
ru
g 
A
dm
in
is
tr
at
io
n;
 G
R
, g
lu
co
co
rt
ic
oi
d 
re
ce
pt
or
; m
C
R
PC
, m
et
as
ta
tic
 
C
R
PC
; N
T
T
D
, N
-t
er
m
in
al
 t
ra
ns
ac
tiv
at
io
n 
do
m
ai
n;
 P
A
R
P,
 p
ol
y(
A
D
P-
ri
bo
se
) 
po
ly
m
er
as
e;
 P
gR
, p
ro
ge
st
er
on
e.
 
O
nc
oT
ar
ge
ts
 a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
19
2.
22
2.
29
 o
n 
29
-D
ec
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
OncoTargets and Therapy 2018:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
7358
Tucci et al
act as partial agonists. Unexpectedly, sensitivity to first-
generation agents such as bicalutamide is maintained.31,32
Other mutations associated with poor response to enzalu-
tamide are L702H, conferring acquired responsiveness to 
glucocorticoids,33 and T878A (previously reported in the 
literature as T877A), resulting in progesterone-mediated 
activation of the AR.30
Preclinical data show that darolutamide, a new oral AR 
antagonist, is able to significantly inhibit the transcriptional 
activity of two of the following mutated forms: T878A and 
F877L.34
AR splice variants
Constitutively, transcriptionally activated ARvs have 
emerged as critical players in the development and progres-
sion of CRPC. ARvs lack the LBD and remain constitu-
tively active even in the absence of binding to androgenic 
hormones: their expression is significantly increased during 
ADT and correlates with PC progression. The most common 
variants are ARV7 and ARV567.35–37
Enzalutamide is able to induce ARvs expression in PC 
cell lines and CRPC xenograft models: as ARvs levels 
increase, drug resistance increases.38 A recent study by 
Antonarakis et al,39 using a circulating tumor cell (CTC) 
assay, showed a significant relationship between ARV7 
mRNA expression and resistance to enzalutamide: ARV7-
positive patients had lower PSA response rates (0% vs 
53%, P=0.004) and shorter OS (median 5.5 months vs not 
reached; P=0.002) than ARV7-negative patients. However, 
some recent evidences show contrasting results: at the 2018 
American Association for Cancer Research Meeting, results 
of an Australian research have been presented. ARV7 and 
ARV9 were detected using a whole blood assay, but no 
significant differences in PSA response rate were found 
between ARV-positive (66%) and ARV-negative patients 
(64%) treated with enzalutamide or abiraterone.40
Because of the clinical relevance of ARvs, several innova-
tive pharmacological strategies are currently under develop-
ment. In detail, a potential strategy is targeting the NTTD 
of the AR, that is, critical for its transcriptional activity. EPI 
compounds are a new class of drugs that prevent the binding 
of transcriptional activator proteins to the AR N-terminal 
domain and decrease the expression of genes regulated by 
both full-length AR and ARV7.41 EPI-506 (ralaniten acetate) 
is a member of EPI compound family that has been tested 
in a Phase I/II study (NCT02606123) in mCRPC patients 
progressed to enzalutamide, abiraterone or both (Table 1). 
Unfortunately, a suboptimal compliance to the high number 
of daily pills (18 capsules/day) was reported at the end of 
Phase I; therefore, it is currently unclear if the clinical devel-
opment of this agent will continue.
Other studies have indicated that targeting coactivators 
and suppressors of AR-mediated transcription may bypass 
secondary resistance. As detailed below, one of these possible 
targets is the coactivator bromodomain containing protein 
(BRD)4: preclinical studies demonstrated that preventing 
its interaction with the NTTD of the AR is associated with 
reduction in ARV7 and ARV567 mRNA and protein expres-
sion and with induction of cell cycle arrest and apoptosis of 
cancer cells.24,42
Another interesting molecule is niclosamide, an FDA-
approved anthelmintic drug, that may induce ARV7 protein 
degradation through a proteasome-dependent pathway.43 In 
enzalutamide-resistant in vitro models, the combination of 
niclosamide and enzalutamide inhibits tumor cell growth 
and induces apoptosis.44 Two Phase I studies are currently 
ongoing to evaluate recommended dose and tolerability of 
niclosamide given together with enzalutamide in CRPC 
patients (NCT03123978 and NCT02532114; Table 1).
Another targeted approach is represented by the het-
erogeneous nuclear ribonucleoproteins (hnRNPAs), whose 
downregulation reduces ARV7 expression and resensitizes 
enzalutamide-resistant cells. Quercetin, a natural polyphe-
nolic compound, reduced the expression of hnRNPAs in 
PC cells.45
Another interesting procedure is based on the use of anti-
sense oligonucleotides to target both the full-length AR and 
its splice variant ARv7. Yamamoto et al46 demonstrated that 
this strategy is able to suppress the growth of enzalutamide-
resistant cell lines and xenografts. Subsequently, the same 
group of authors evaluated the combination of AR antisense 
oligonucleotides with siRNA targeting clusterin, a chap-
erone protein involved in the mechanisms of resistance to 
AR inhibition. They used an innovative lipid nanoparticle 
formulation of siRNA to facilitate tumor cell permeation and 
retention. Results demonstrated a significantly decreased 
tumor cell growth, both in vivo and in vitro, in enzalutamide-
resistant CRPC models.47
The observation that a long noncoding RNA, metastasis-
associated lung adenocarcinoma transcript 1 (Malat1), is 
requested for enzalutamide-induced ARV7 production 
paved the way to a new approach to overcome resistance. 
Wang et al48 demonstrated that treatment with Malat1 small 
interfering RNA inhibits ARV7 expression in cell lines and 
significantly reduces tumor growth in enzalutamide-resistant 
xenografts.
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New promising targets include the BRD2, BRD3 
and BRD4, chromatin readers of the bromodomain and 
extra-terminal (BET) family. Particularly, BRD4 is a co-
regulator of AR, and the inhibition of this family of proteins 
significantly decreased AR signaling and growth of a patient-
derived xenograft model of CRPC with both ARV7 expres-
sion and AR amplification.49 The efficacy of BET inhibitors 
has been recently demonstrated in enzalutamide-resistant 
PC models: these molecules markedly repressed ARV7 
expression in vitro and inhibited tumor cell growth in vivo.50 
Three clinical trials are currently ongoing to evaluate the 
combination of enzalutamide with different BET inhibitors: 
ZEN-3694 (NCT02711956), GS-5829 (NCT02607228) and 
GSK525762 (NCT03150056; Table 1).
Finally, several natural substances from traditional 
Chinese medicine have recently shown interesting effects 
against PC cells both in vitro and in vivo. For example, 
Han et al51 demonstrated that low dose of triptolide, an active 
compound extracted from the herb “Thunder God Vine”, inhib-
ited phosphorylation of both full-length and truncated AR. A 
synergistic effect was noted in the combination with enzalut-
amide. Other natural products with promising anti-PC activity 
are urolithins (metabolites of human microflora), rhizochalinin 
(a marine compound), sintokamide (a chlorinated peptide), 
all targeting AR and ARvs with several mechanisms.51
Altered steroidogenesis
Testosterone and 5α-dihydrotestosterone are sex steroid hor-
mones, mainly synthesized from cholesterol in the testes. Only 
5%–10% of their synthesis take place in the adrenal glands.52
The intratumoral synthesis of these hormones, quite 
limited in untreated primary PC, increases in CRPC patients, 
and both cholesterol and weak androgens, such as androstene-
dione and dehydroepiandrosterone, synthesized in the adrenal 
glands, may act as precursors.53 The increased intratumoral 
level of androgens promotes both paracrine and autocrine acti-
vation of the AR, regardless of systemic hormone levels.54
Preclinical studies, conducted on both cell lines and xeno-
grafts, have suggested that enzalutamide resistance may be 
related to an overexpression of genes encoding for enzymes 
involved in androgen biosynthesis: SRD51A, HSD3β1 and 
AKR1C3.55 One of these enzymes, AKR1C, is a potential 
target for pharmacological approaches. In both in vitro and 
in vivo preclinical models, indomethacin, an NSAID, inhibits 
AKR1C activity and resensitizes CRPC to enzalutamide.56 
A Phase I/II trial, evaluating the combination of indomethacin 
and enzalutamide in CRPC patients, is currently recruiting 
patients (NCT02935205; Table 1).
AR-independent mechanisms of 
resistance
Overexpression and upregulation of 
glucocorticoid receptor (GR)
The GR is a member of the steroid hormone nuclear receptor 
family, expressed in almost all human tissues. Like AR, the 
GR consists of four functional domains: the DNA and the 
ligand binding, the N-terminal and the hinge region. More-
over, these two receptors share response elements in target 
genes and have overlapping transcriptomes.57
The GR resides in the cytoplasm, complexed with heat 
shock proteins. The binding of glucocorticoids promotes its 
homo-dimerization and translocation in the nucleus, where 
GR mediates transcriptional activation, influencing target 
gene expression.57
Puhr et al58 recently investigated GR expression and 
its functional significance in both PC cell lines and human 
tissues obtained from 177 PC patients. It was observed that 
GR expression is low in primary PC tissue and significantly 
increased during long-term treatment with enzalutamide. 
These results confirm previous findings of Arora et al59 which 
demonstrated how GR overexpression conferred resistance 
to enzalutamide. Particularly, AR inhibition may determine 
GR overexpression and upregulation and able to restore the 
expression of certain AR target genes. In the same study, 
dexamethasone, that is a potent GR agonist, conferred 
resistance to enzalutamide, whereas GR antagonists restored 
sensitivity.
Unexpectedly, in a randomized Phase II trial comparing 
daily administration of dexamethasone vs prednisone in men 
with chemotherapy-naïve CRPC, dexamethasone induced a 
PSA response rate of 47% vs 24% (P=0.05).60 A pilot study 
(NCT02491411) is currently recruiting patients with mCRPC, 
who were previously treated with enzalutamide and docetaxel, 
to study how dexamethasone may contrast GR overexpres-
sion, allowing the retreatment with enzalutamide (Table 1). 
Another trial is evaluating the safety and efficacy of the GR 
antagonist CORT125281 in combination with enzalutamide 
in men with mCRPC (NCT03437941; Table 1).
Recently, mifepristone, a synthetic steroidal antagonist 
of both GR and progesterone receptor, has gained great 
interest as a potential agent against PC. Unfortunately, 
although a clinical trial evaluating the combination of mife-
pristone and enzalutamide (NCT02012296) is still ongoing 
(Table 1), recent reports questioned the real efficacy of this 
association.61 Moreover, in preclinical models of PC, mife-
pristone significantly reduced the efficacy of enzalutamide, 
probably because of its partial AR agonist activity.62
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epithelial–mesenchymal transition (eMT)
The transition of epithelial into mesenchymal cells is an 
essential physiological mechanism for both embryonic 
development and wound healing. Unfortunately, this pro-
cess also contributes pathologically to fibrosis and cancer 
metastasis.63
Epithelial phenotype is characterized by apical–basal cell 
polarity, intercellular adhesion and cohesive interaction and 
lack of mobility of individual cells. Mesenchymal cells are 
completely different, being neither adherent nor apically 
polarized.64
EMT may be induced by ADT in metastatic PC, and 
increasing evidence shows that this process promotes tumor 
progression and drug resistance. The activation of differ-
ent pathways, such as TGF-β and SMAD, modulates the 
activity of some transcriptional factors such as Snail and 
Twist, reducing the expression of e-cadherin, a key event in 
EMT.65 Twist is a transcriptional factor that is upregulated 
during ADT and enzalutamide treatment. This mechanism, 
together with protein kinase C (PKC) activation, is respon-
sible for the occurrence of resistance. Up to now, no direct 
Twist inhibitors are available; therefore, Shiota et al66 tested 
the small molecule Ro318220, a PKC inhibitor, to revert 
resistance in PC cell lines. The combination of Ro318220 
with enzalutamide produced promising results, increasing 
the therapeutic effects of androgen depletion. Another tran-
scriptional factor, Snail, can promote resistance to enzalu-
tamide and increase migration and invasion of PC cells. 
Indeed, an elevated expression of Snail was documented in 
enzalutamide-resistant PC cells, while its downregulation 
resensitized cells to the pharmacological treatment.67
Recent studies by Liu et al68 showed that metformin, a 
well-known oral hypoglycaemic agent, reverts resistance 
in PC cell lines and mice xenografts. In detail, metformin 
exerts its effects repressing TGF-β1/STAT3 pathway, whose 
activation instead induced EMT. Currently, there are two 
clinical trials recruiting patients to evaluate the role of met-
formin as anticancer agent in combination with enzalutamide 
(NCT02339168 and NCT02640534; Table 1).
Another Phase II trial (NCT02452008) is currently ongo-
ing to evaluate the efficacy of the TGF-β inhibitor, galuni-
sertib, given in combination with enzalutamide (Table 1).
Neuroendocrine transformation
Prostate adenocarcinoma may transdifferentiate into neu-
roendocrine PC (NEPC) as an adaptive response to intense 
androgen signaling inhibition. Infrequently present at the 
time of diagnosis, NEPC usually develops at later stages 
of treatment and is characterized by rapid growth and poor 
prognosis. When transformation to NEPC occurs, AR expres-
sion is low or absent, so these tumors are typically resistant 
to AR-directed therapies such as enzalutamide.69
In these cases, even without robust clinical evidence, 
cisplatin or carboplatin combined with etoposide is the most 
commonly used regimen. The Phase II trial GETUG P01 
demonstrated an overall response rate (ORR) of ,9% and a 
median OS of 9.6 months (95% CI 8.7–12.7) in a cohort of 
60 patients with either NEPC or visceral metastasis treated 
with the combination of carboplatin and etoposide every 
3 weeks.70 The combination of platinum and taxane has been 
tested in patients with mixed high-grade adenocarcinoma 
and NEPC, reporting an ORR of 41% and a median OS of 
12 months.71
Ongoing genomic and biochemical research aims to 
better characterize these tumors, looking for potential new 
targets.
One of the most promising targets is Aurora Kinase A 
(AUR-KA), an oncogene whose overexpression/amplification 
has been found in 40% of NEPC patients. AUR-KA stabi-
lizes N-myc and cooperatively promotes neuroendocrine 
transdifferentiation.72 When evaluated in 59 metastatic 
NEPC patients, the AUR-KA inhibitor alisertib demonstrated 
modest activity. Preliminary results of this Phase II clinical 
trial (NCT01799278) were presented at the 2016 European 
Society of Medical Oncology (ESMO) meeting: the 6-month 
progression-free rate was 11.1% (16.3% for patients with 
pathologically confirmed NEPC; 95% CI 5%–31.6%). Of 
note, two patients obtained an exceptional response, with 
complete regression of liver metastasis. The identification 
of biomarkers predictive of response would be crucial for 
future developments (Table 1).
Another target is the enhancer of zeste homolog 2 
(EZH2), an epigenetic reprogramming gene, involved in 
NEPC development. Different EZH2 inhibitors, including 
GSK-126/343/503, have recently been developed, and in 
preclinical studies they showed growth inhibition of CRPC 
cell lines. Moreover, the block of EZH2 may resensitize to 
enzalutamide PTEN and Rb double knockout mice.73
Activation of other pathways
The acquired resistance to enzalutamide may also be medi-
ated by the activation of parallel signaling pathways, includ-
ing PI3K, HER2 and NF-κB.
The PI3K–AKT–mTOR pathway regulates all major 
cellular processes: cell growth, proliferation, apoptosis and 
protein synthesis. Its aberrant activation is implicated in PC 
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development and progression.74 The cross talk between the 
AR and PI3K was demonstrated in preclinical models by 
Carver et al.75 While the inhibition of one pathway activated 
the other, in murine models and human xenografts, the con-
comitant inhibition of AR and PI3K induced PC regression. 
These results were confirmed by Thomas et al,76 both in vitro 
and in vivo, testing the combination of the AKT inhibitor 
AZD5363 with the antiandrogen, bicalutamide. Two trials 
are ongoing to evaluate the association of the AZD5363 
with enzalutamide: one is a Phase I study enrolling patients 
with specific AKT mutations (NCT03310541), whereas the 
other is enrolling men with mCRPC already treated with 
one or two lines of chemotherapy and at least 12 weeks of 
abiraterone, without molecular selection (NCT02525068; 
Table 1).
There are different classes and subtypes of PI3K: class IA 
includes two isoforms, p110 α and β, both ubiquitously 
expressed. The former is associated with insulin and growth 
factor pathway, and the latter regulates cell mitosis and 
survival. Several attempts have been made to develop iso-
form β-specific inhibitors, including the recent synthesis of 
BL140. This agent effectively suppressed PC growth in all PC 
lines tested77 and exhibited a stronger inhibitory effect than 
GSK2636771, the only PI3K-β inhibitor currently assessed 
in a clinical trial (NCT02215096; Table 1).
Because of the cross talk between PI3K and the insulin-
like growth factor (IGF) pathway, a Phase Ib/II trial 
(NCT02204072) is ongoing to investigate the combination of 
enzalutamide with BI836845, a humanized IgG1 monoclonal 
antibody targeting IGF1/2.
The direct inhibition of mTOR is another potential 
therapeutic strategy, and two Phase I trials are evaluating the 
combination of enzalutamide, respectively, with everolimus 
(NCT02125084) and CC-115 (NCT02833883), while the 
single-agent mTOR inhibitor, MLN0128, is evaluated in a 
Phase II trial (NCT02091531; Table 1). Another Phase II trial 
(NCT02407054) is assessing the PI3K/mTOR dual inhibitor, 
LY3023414, in men with mCRPC (Table 1).
The HER2/HER3 pathway, through the activation of 
PI3K/AKT, may represent another mechanism of resistance 
to enzalutamide. The cross talk between the HER2/HER3 
and the AR has been extensively demonstrated. Increased 
HER2 expression was documented in enzalutamide-resistant 
PC, and enzalutamide may induce HER2 expression in PC 
cell lines. The combination of enzalutamide and lapatinib, 
a tyrosine kinase inhibitor (TKI) of both HER2 and EGFR 
receptors, improved the response rate compared to enzalu-
tamide alone.78
The activation of NF-κB/p52 pathway also contributes 
to the development of enzalutamide resistance. In vitro 
studies demonstrated an activation of NF-κB/p52 and over-
expression of ARvs in PC cell lines chronically treated with 
enzalutamide. Conversely, the downregulation of NF-κB/
p52 reduced ARV7 expression and resensitized PC cells to 
enzalutamide.79 Moreover, NF-κB regulates the expression of 
several cytokines, in both malignant and normal tissues. IL-6 
is highly expressed in CRPC, and it modulates transcriptional 
activity of the AR. Up to now, experimental therapies against 
IL-6 have not been successful.80
Autophagy
Autophagy is an adaptive process to maintain cellular homeo-
stasis through degradation and recycling of cellular compo-
nents. There is a physiological balance between autophagy 
and apoptosis, which may be lost in cancer development, 
where dysfunction of apoptosis is a common phenomenon. 
The consequent upregulation of autophagy may be used as a 
source of nourishment by high-proliferative tumor cells.81
The AR is a key modulator of autophagy. Treatment 
with bicalutamide of PC cell lines induced autophagy,82 
and a similar effect was reported by Nguyen et al,83 within 
in vitro and in vivo PC models. The autophagy modulators 
such as clomipramine and metformin significantly improved 
enzalutamide activity reducing tumor growth within in vivo 
mouse models.
Autophagy may also be chaperone mediated. Clusterin, 
a heat-shock chaperone-like protein is induced by AR 
antagonists such as enzalutamide. The coadministration of 
enzalutamide and OXG-011, a clusterin inhibitor, enhanced 
apoptosis and delayed progression, within both in vitro and 
in vivo PC models.84
The immune system activation
Despite immunotherapy is an intriguing therapeutic option 
and the initial preclinical data with immune checkpoint 
inhibitors are encouraging, its clinical use in PC is still 
very limited. In preclinical mouse models with PC resistant 
to enzalutamide, Bishop et al85 demonstrated an increased 
expression of both intratumoral PD-L1 and circulating PD-
L1/2-positive dendritic cells. These data were confirmed 
in vivo, comparing blood samples of patients progressing 
during enzalutamide with samples of treatment-naïve or 
treatment-responsive patients. However, the current evi-
dence about the predictive role of both PD-1 and PD-L1 as 
biomarkers of response to specific immunotherapy is still not 
defined. Moreover, PC is characterized by minimal immune 
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cell infiltrate and a relatively low mutational burden, both 
known as negative predictive factors of response to immu-
notherapy in other tumors.86
Having all those “caveats” in mind, a Phase II single-arm 
clinical trial demonstrated a meaningful activity of pembroli-
zumab, an anti-PD-1 checkpoint inhibitor already approved 
for the treatment of other solid tumors, in CRPC patients 
after progression with enzalutamide. Of the 10 patients 
enrolled, three experienced a biochemical response and two a 
radiological response, including a patient with microsatellite 
instability (MSI), which has been shown to be a predictive 
factor for this therapeutic approach.87 Combination therapy of 
pembrolizumab and enzalutamide is currently under clinical 
investigation in the Phase I KEYNOTE 365 (NCT02861573) 
and in the Phase II KEYNOTE 199 (NCT02787005; Table 1). 
Other trials are evaluating the anti-PD1 checkpoint inhibitor, 
nivolumab (NCT03338790), and the anti-PD-L1, atezoli-
zumab (NCT03016312; Table 1).
Available results from the Phase III trial, CA184-043, 
testing the anti-CTLA4 ipilimumab vs placebo after RT in 
patients with mCRPC who had progressed after docetaxel 
chemotherapy, showed no difference in OS between treat-
ment arms. However, a post hoc analysis reported a possible 
benefit in patients with good prognostic factors (median 
OS 22.7 vs 15.8 months, HR 0.62, 95% CI 0.45–0.86, 
P=0.0038).88
Current clinical trials are exploring new promising 
target agents, such as AZD5069, a chemokine receptor 2 
(CXCR2) antagonist, in combination with enzalutamide 
(NCT03177187; Table 1).
Currently, the only FDA-approved immunotherapy 
remains sipuleucel-T, an autologous cellular treatment for 
patients with mCRPC with mild or no symptoms.86
Liquid biopsy: a promising tool 
for recognizing mechanisms of 
resistance
Liquid biopsy is a noninvasive blood test to detect CTCs 
or cancer-derived nucleic acids, such as DNA and RNA. It 
is clearly less invasive than a traditional tissue biopsy and 
may better characterize the tumor molecular assessment, 
recognizing mechanisms of resistance and guiding thera-
peutic choices.89
In PC patients, the number of CTCs correlates with disease 
outcome. Major efforts have been done to characterize the 
expression of ARvs in the contest of CTCs. Unfortunately, as 
previously described in this review, the correlation between 
ARvs detection in CTCs and resistance to enzalutamide 
treatment has not been homogeneously confirmed in all the 
series.39,40 Probably, this could be due to the development of 
various and heterogeneous methods of isolation, based on 
different definitions of CTCs. By now, CellSearch® is the 
only CTC detection platform approved by the FDA, but it is 
not currently used in common clinical practice.89
Another interesting approach is the whole genomic 
analysis of pooled CTCs. Gupta et al90 enrolled patients 
with mCRPC with primary or acquired resistance to new-
generation hormonal drugs, identifying potentially actionable 
genomic alterations, such as BRD4, PI3K and AR.
As mentioned earlier, the direct sequencing of cell-free 
DNA may also provide useful information. Initially, the atten-
tion was focused on the detection of AR gene aberrations, 
related to both enzalutamide and abiraterone resistance.91 
Subsequently, the analysis has also been extended to other 
genes and their potentially actionable alterations, namely 
Wyatt et al92 collected plasma samples of 65 patients with 
mCRPC treated with enzalutamide. Cell-free DNA was iso-
lated and sequenced: not only mutations and amplifications 
of AR but also PI3K and damage repair genes were detected, 
at baseline and, even more, at disease progression.
To better understand primary resistances, Annala et al93 
collected plasma specimens and analyzed cell-free DNA from 
patients with mCRPC, before starting treatment with either 
enzalutamide or abiraterone, within a randomized Phase II 
trial. Among the genomic alterations detected, mutations of 
BRCA, ATM and p53 defects were associated with primary 
resistance and poor outcome. AR gene structural rear-
rangements were frequently found in patients with primary 
resistances, but their prognostic role was not confirmed. On 
the other hand, this analysis showed that a high rate of copy 
number gene changes had no significant prognostic and 
predictive value. These data have been confirmed by Belic 
et al94 that the AR amplification alone is not predictive of 
resistance to enzalutamide. Interestingly, authors found a 
correlation between blood levels of lactate dehydrogenase 
and the detection of cell-free DNA.
Genomic and transcriptomic 
analyses to identify mechanisms of 
resistance
To better understand the mechanisms of resistance to 
enzalutamide and develop new therapeutic strategies, both 
genomic and transcriptomic analyses have been recently per-
formed. Following the demonstration that multiple genomic 
alterations may contribute to the development of resistance, 
King et al95 tried to organize these alterations into different 
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pathways, identifying those potentially actionable: MEK, 
EGFR, RAS and NF-κB. Similarly, with an integrative 
analysis of four transcriptome datasets, a group of researchers 
from the University of Shanghai tried to identify the differ-
ent expression of key genes in both resistant and sensitive 
enzalutamide cell lines.96 One of the patterns explored was 
ubiquitin-mediated proteolysis: its abnormal function may 
lead to enzalutamide resistance.
Looking forward: a more effective 
interference with AR pathway
Among the drugs designed to overcome the resistance 
induced by enzalutamide, those with more advanced clinical 
data are apalutamide and darolutamide. Their safety, activity 
and efficacy are being evaluated in both HSPC and CRPC 
patients, in the metastatic and locally advanced setting. The 
unexpected negative outcome of the ARMOR 3-SV study 
led to an early discontinuation of the development program 
of galeterone, another promising innovative antiandrogen 
drug (NCT02438007).
Apalutamide
Apalutamide (also known as ARN-509) is an orally available, 
selective and irreversible AR antagonist, which inhibits AR 
nuclear translocation, preventing the binding of AREs.97
Apalutamide was shown to reduce the proliferation of PC 
cells in in vitro models and to induce a higher tumor regres-
sion than enzalutamide in murine tumor models of CRPC.98 
A first-in-human Phase I study (ARN-501-001) demonstrated 
that treatment with ARN-509 was safe and well tolerated.99 
Promising data of drug activity were confirmed in the Phase 
II portion of the same trial; apalutamide showed durable PSA 
response in nonmetastatic and early mCRPC, untreated with 
new-generation hormonal agents and chemotherapy. In the 
nonmetastatic CRPC group, median time to PSA progression 
was 24 months, and the metastasis-free survival at 12 months 
was 87%. However, results were substantially worse in 
mCRPC patients pretreated with abiraterone, whose median 
time to PSA progression was 3.7 months.100
More recently, the Phase III trial, SPARTAN, showed that 
in patients with high-risk, nonmetastatic CRPC, the addition 
of apalutamide to ADT reduced the risk of distant metastasis 
or death by 72% (HR 0.28, 95% CI 0.23–0.35, P,0.0001) 
and prolonged median metastasis-free survival by more than 
20 months compared to placebo.17
Another Phase III trial (NCT02257736) is currently 
comparing the combination of apalutamide and abirater-
one vs abiraterone alone in chemotherapy-naïve patients 
(Table 1). Other Phase I/II trials are testing the combination 
of apalutamide with docetaxel (NCT03093272), abirater-
one (NCT03360721, NCT03098836, NCT0317385911), 
both docetaxel and abiraterone (NCT02913196) and even 
everolimus (NCT02106507; Table 1).
Darolutamide
Darolutamide (also known as ODM-201) is a novel, 
nonsteroidal highly selective AR inhibitor, with a superior 
AR-binding affinity than enzalutamide. Unlike bicalutamide, 
which showed significant agonism in AR-overexpressing 
cells, darolutamide demonstrated full AR antagonist proper-
ties, even against clinically relevant AR mutations associ-
ated with enzalutamide resistance: AR F877L, W742L and 
T877A.101 Based on in vitro studies, darolutamide has a low 
potential for drug–drug interaction with other substances 
metabolized by CYP enzymes.102
It is well known that enzalutamide and its active 
metabolites cross the blood–brain barrier, even if the recent 
UPWARD study has shown that the incidence of seizures, 
initially considered as a typical AE potentially associated 
with the administration of enzalutamide, is actually similar 
in patients with mCRPC and seizure risk factors, regardless 
of enzalutamide exposure.103 In any case, there is no evidence 
that darolutamide significantly penetrates the blood–brain 
barrier, and it could be consequently associated with a lower 
risk of inducing seizures.101
The first-in-man study was an open-label, Phase I/II 
dose escalation–expansion cohort trial.104 Darolutamide 
showed a favorable safety profile, and no dose-limiting 
toxic effects were reported. Moreover, clinical activity was 
reported, mainly in patients who not previously treated with 
CYP17 inhibitors. The Phase I ARAFOR trial evaluated 
both the bioavailability and activity of darolutamide in men 
with chemotherapy-naïve and CYP17 inhibitor-naïve CRPC: 
a PSA decline $50% was shown in 83% of the 30 patients 
enrolled. Disease control was observed in 78% of bone and 
91% of soft tissue lesions.105
Two randomized, double-blind, placebo-controlled, 
Phase III trials are ongoing: ARAMIS (NCT02200614, active 
but not recruiting) and ARASENS (NCT02799602, active 
and recruiting patients; Table 1). In detail, ARAMIS is 
evaluating efficacy and safety of darolutamide in men with 
high-risk nonmetastatic CRPC. The risk of developing metas-
tasis was defined by confirmed rising PSA levels and short 
PSA doubling time. ARASENS is testing the same drug in 
addition to standard ADT and docetaxel in metastatic HSPC. 
The primary end point of the study is OS.
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Because of the growing value of patient-reported out-
comes in the assessment of the balance between symptom 
control and the impact on the quality of life of side effects, 
the Phase II ODENZA trial, not yet recruiting, will assess 
patients’ preference between darolutamide and enzalutamide 
through specific questionnaires (NCT03314324; Table 1).
Galeterone
Galeterone is a selective, multitargeted antiandrogen agent, 
characterized by at least three different mechanisms of action: 
inhibition of the enzyme CYP17, antagonism and degradation 
of both full-lenght AR and ARvs, including ARV7. Preclini-
cal studies both in vitro and in vivo have demonstrated that 
galeterone reduces the androgen-dependent proliferation of 
human PC cells.106
The Phase I multicenter dose-escalation clinical trial, 
ARMOR 1, included 49 patients with progressive CRPC 
not treated with chemotherapy or the other new generation 
hormonal agents.107 The study evaluated safety and activity 
of oral galeterone, whereas the first part of the Phase II 
trial ARMOR 2 tested a spray dry dispersion formulation 
of the drug. Overall, galeterone was well tolerated, with an 
acceptable safety profile in all cohorts. PSA responses were 
observed at all doses in ARMOR 1, particularly 42% of 
patients treated at the highest dose of 2,600 mg/die showed 
a PSA reduction of $50%.
The dose expansion cohort of ARMOR 2 trial enrolled 95 
patients treated with galeterone at 2,550 mg/die. Promising 
efficacy data were reported with PSA reduction of $50% 
observed in 70% of evaluable patients.106
Based on these clinical results, a Phase III study was 
conducted (NCT02438007). The ARMOR 3-SV was an 
open-label, randomized trial of galeterone compared to 
enzalutamide in men with ARV 7-positive mCRPC. Unfor-
tunately, according to the Independent Data Monitoring 
Committee recommendation, the study was prematurely 
closed. A careful analysis of all safety and efficacy data 
concluded that the trial would hardly have reached the pri-
mary end point.
Beyond the AR: the contemporary role of 
AR-independent pathway inhibition
PC is a heterogeneous disease in which both AR-positive and 
AR-negative neoplastic cells coexist, and both contribute to 
cancer progression.19,21
Adaptive response to hormonal therapy is mediated by the 
activation of AR-dependent pathways, but at the same time, 
it can be attributable to crucial mechanisms of progression 
bypassing AR signaling.19,21 Endocrine therapy, in fact, block-
ing AR-positive cells can induce treatment resistance causing 
clonal selection and the consequent growth of cellular clones 
independent of AR signalling.19
These biological evidences represent the basis for the 
administration of chemotherapy in association with endocrine 
therapy, in the attempt to interfere also with AR-independent 
survival pathways, inhibiting AR-negative cells; such 
approach could delay the development of hormonal treat-
ment resistance mechanisms blocking the growth of a larger 
amount of neoplastic cells.19,21
In this context, recent evidence showed that adding 
docetaxel to ADT in patients with high-risk or high-volume 
hormone-sensitive metastatic disease is able to induce a sig-
nificant improvement in OS compared to ADT alone.12–14
These preclinical and clinical findings provide the ratio-
nale to combine new generation hormonal therapies such as 
enzalutamide with chemotherapy. A Phase II study testing 
the combination of ADT and docetaxel with the addition of 
enzalutamide in metastatic HSPC patients is ongoing. The 
aim of the trial is to evaluate whether ADT plus docetaxel 
plus enzalutamide may increase treatment efficacy compared 
to ADT plus docetaxel (NCT03246347; Table 1). Another 
trial is investigating the activity of docetaxel added to enzalu-
tamide in overcoming enzalutamide resistance in mCRPC 
patients (NCT02288247; Table 1). Furthermore, two studies 
are evaluating the efficacy of the combination of enzalut-
amide with cabazitaxel in mCRPC patients (NCT02522715, 
NCT03110588; Table 1).
Recently, Robinson et al108 prospectively investigated 
the whole-exome and transcriptome sequencing from soft 
tissue or bone secondary lesions in 150 mCRPC patients. 
Aberrations of AR were detected at higher rate than expected 
(63%). Furthermore, among non-AR-related alterations, 
DNA repair gene pathways (BRCA2, BRCA1 and ATM) 
were commonly altered (19.3%).
In a Phase II trial, 50 mCRPC patients were treated with 
the PARP inhibitor, olaparib.109 Next-generation sequencing 
detected DNA repair gene aberrations in 16 patients; among 
these patients, 14 patients had objective response and the 
response rate was higher than in those patients who were 
not harboring DNA repair gene alterations.
These biological and clinical data confirm the crucial 
role of DNA repair gene mutations as a tumor cell survival 
pathway in CRPC patients and provide a rationale for the 
use of PARP inhibitors. Several studies are ongoing, testing 
the activity of PARP inhibitors alone or in combination with 
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new generation hormonal therapies in metastatic prostate 
carcinoma (Table 1).
Future perspectives and conclusion
In recent years, several researches regarding CRPC showed 
resistance mechanisms to ADT mainly due to AR ampli-
fication or mutation.19,21 The identification of these escape 
mechanisms allowed to understand that AR pathway activity 
persists despite low levels of serum testosterone and favored 
the development of new generation AR antagonists such as 
enzalutamide.19,21
The advent of new generation hormonal therapies set 
the stage for a new era in the treatment landscape of CRPC. 
Although these agents showed to increase OS, a relevant 
proportion of patients do not benefit at all or acquire resis-
tance during treatment.
Primary and secondary resistance to enzalutamide is 
a multifactorial phenomenon which depends on not only 
ligand-dependent and ligand-independent AR activation but 
also pathways bypassing AR signaling.
Taking into account the future shift for enzalutamide in 
the early disease stages, in the next years, physicians will 
face several therapeutic challenges. The most important 
challenge will be a more complete knowledge of hetero-
geneity of PC. Nowadays, we know that metastatic PC is 
a heterogeneous disease, in which AR-positive and AR-
independent neoplastic cells coexist19 and in which AR 
aberrations responsible for enzalutamide resistance could be 
present at various degrees.19,21 This heterogeneity is the main 
reason for different biological behaviors and particularly for 
different responses to new-generation hormonal therapies 
among various PCs.
Future in vitro and in vivo studies should enable us to 
obtain a better understanding of biological PC heterogeneity 
to identify patients who will not respond to enzalutamide 
therapy or those who will likely develop acquired resistance 
in a few months. The identification of predictive biomarkers 
of response, as well as the detection of PC molecular subtypes 
based on proteomic and genomic assessment, will be critical 
to improve the activity of enzalutamide and to identify new 
approaches for bypassing resistance to personalize treatment 
on the basis of PC biology.
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